Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial

Diabetes and Vascular Disease Research

Volumn 12, Issue 6, 2015, Pages 455-462

  Groop, Per Henrik ^a,b,c   Cooper, Mark E ^c   Perkovic, Vlado ^d   Sharma, Kumar ^e,f   Schernthaner, Guntram ^g   Haneda, Masakazu ^h   Hocher, Berthold ⁱ   Gordat, Maud ^j   Cescutti, Jessica ^j   Woerle, Hans Juergen ^k   Von Eynatten, Maximilian ^k  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^h ASAHIKAWA MEDICAL COLLEGE   (Japan)

ⁱ UNIVERSITY OF POTSDAM   (Germany)

^j BOEHRINGER INGELHEIM   (France)

^k BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

albuminuria; chronic kidney disease; Dipeptidyl peptidase 4 inhibition; glycaemic control; linagliptin; type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; LINAGLIPTIN; PLACEBO; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINE LEVEL; ADOLESCENT; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY DISEASES; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY DISEASES; LINAGLIPTIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945315616     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164115579002     Document Type: Article

References (34)

1. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60: 850-886.
2. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37: S14-S80.
3. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
4. Monami M, Dicembrini I, Martelli D, et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27: 57-64.
5. Chan JC, Scott R, Arjona Ferreira JC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008; 10: 545-555.
6. Groop PH, Del Prato S, Taskinen MR, et al. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 2014; 16: 560-568.
7. Kothny W, Shao Q, Groop PH, et al. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14: 1032-1039.
8. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36: 237-244.
9. Nowicki M, Rychlik I, Haller H, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230-1239.
10. Mentlein R,. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
11. Schlatter P, Beglinger C, Drewe J, et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141: 120-128.
12. Chatelet F, Brianti E, Ronco P, et al. Ultrastructural localization by monoclonal antibodies of brush border antigens expressed by glomeruli. I. Renal distribution. Am J Pathol 1986; 122: 500-511.
13. Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens 2014; 32: 2211-2223.
14. Stiller D, Bahn H, August C,. Demonstration of glomerular DPP IV activity in kidney diseases. Acta Histochem 1991; 91: 105-109.
15. Pala L, Mannucci E, Pezzatini A, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003; 310: 28-31.
16. Yang J, Campitelli J, Hu G, et al. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007; 81: 272-279.
17. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012; 340: 248-255.
18. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092.
19. Alter ML, Ott IM, von Websky K, et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119-130.
20. Nistala R, Habibi J, Aroor A, et al. DPP4 Inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat. Obesity 2014; 22: 2172-2179.
21. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014; 63: 2120-2131.
22. Ishibashi Y, Matsui T, Maeda S, et al. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol 2013; 12: 125.
23. Kroller-Schon S, Knorr M, Hausding M, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012; 96: 140-149.
24. Nakashima S, Matsui T, Takeuchi M, et al. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res 2014; 46: 717-721.
25. Fujita H, Taniai H, Murayama H, et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1alpha in type 2 diabetic patients with incipient nephropathy. Endocr J 2014; 61: 159-166.
26. Hattori S,. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011; 58: 69-73.
27. Sakata K, Hayakawa M, Yano Y, et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE)-receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev 2013; 29: 624-630.
28. Groop PH, Cooper ME, Perkovic V, et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36: 3460-3468.
29. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
30. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
31. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013; 24: 1901-1912.
32. Inrig JK, Califf RM, Tasneem A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 2014; 63: 771-780.
33. De Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503.
34. Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. Epub ahead of print 2015. doi: 10.1053/j.ajkd.2015.03.024.